SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Experimental/Growth Hormone SecretagoguesResearch peptide

Sermorelin

A 29-amino-acid GHRH analog historically used in pediatric GH-deficiency evaluation and adult anti-aging protocols.

Educational explainer of a research peptide. Profiles in this section deliberately omit clinical-trial citations, dosing protocols, and purchase links. Not FDA-approved as a supplement; not a recommendation to use.

Overview

Sermorelin is the first 29 amino acids of natural growth-hormone-releasing hormone — the minimum sequence needed to bind the GHRH receptor.

Source
  • Synthesized in research and compounding laboratories
Forms
  • Subcutaneous injection
  • Lyophilized vial reconstituted in bacteriostatic water

Mechanism of action

Stimulates the anterior pituitary to release growth hormone via the GHRH receptor, mimicking the body's own GHRH signal.

Pathways
  • · GHRH-R → cAMP → GH release
Receptors
  • · GHRH receptor
Hormones
  • · Growth hormone
  • · IGF-1

How it acts on the body

Because sermorelin is structurally closer to native GHRH than to engineered analogs, it has a short half-life (around 10–20 minutes) — long enough to elicit a GH pulse, short enough that the pituitary's somatostatin feedback remains untouched. This is why it has historically been considered a 'physiological' GH support rather than a true performance peptide.

Functionally it acts on the hypothalamic-pituitary-somatotropic axis without bypassing it. The pituitary still controls how much GH it releases, so sermorelin tends to restore a more youthful release pattern rather than override it. With age, GHRH output declines while somatostatin tone rises; sermorelin works against the first half of that imbalance.

Hormonal & endocrine impact

How this peptide is reported to shift specific hormones and signaling molecules. Directionality reflects research literature and preclinical models, not clinical prescribing data.

Projected hormonal trajectory
Illustrative curves derived from reported direction of effect. Not measured patient data.

Curves are schematic shapes (sigmoid for increases/decreases, damped oscillation for modulation/stabilization) anchored to a 100% baseline. They communicate direction and tempo of change reported in research literature — not absolute hormone concentrations.

Growth hormoneIncreases
Restores age-attenuated GH pulses, especially overnight.
IGF-1Increases
Modest, gradual rise — typically within physiological range.
SomatostatinStabilizes
Feedback control intact, lower risk of HPA-axis suppression.
Cortisol & prolactinStabilizes
No clinically meaningful change reported.

Effects on the body

Increases
Endogenous GH release
Supports
Sleep quality and recovery

Organ system effects

Endocrine

Targets the natural pituitary axis without bypassing feedback control.

Skeletal Muscle

Modest improvements in lean tissue with long-term use.

Reported effects

Drawn from preclinical research, anecdote, and small-scale clinical observation. No evidence grades are assigned — most peptides on this page lack rigorous human trials.

  • Restores more youthful GH pulse patterns
  • May improve sleep, energy, and recovery
  • Preserves negative feedback (lower risk of suppression vs exogenous HGH)

Potential side effects

Common
  • · Injection-site reaction
  • · Flushing
  • · Headache
Rare
  • · Hyperactivity
  • · Nausea
Serious
  • · Possible insulin-sensitivity changes with prolonged use

Drug interactions

Glucocorticoids
Blunt GH response.
moderate
Thyroid hormones
May alter response; monitor labs.
minor

Pairing context

Often combined with
  • GHRPs (ipamorelin)
    Common research synergy for stronger GH pulses.
Avoid combining with
  • Active malignancy
    Avoid stimulating the GH/IGF-1 axis.
Important. Research peptides described here are not FDA-approved supplements. Supplement Scholar does not endorse, recommend, or link to any source for purchase. Consult a qualified clinician before considering any peptide therapy.